Our Pipeline

We are pioneering for patients and are working tirelessly to bring value to all our stakeholders.

Our pipeline represents a commitment to transforming the way patients are treated, with programs in discovery through to late-stage clinical development.

Oncology

CAR-T

Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
5101
CD19
Non-Hodgkin’s lymphoma (NHL)
5201
CD19
Chronic lymphocytic leukemia (CLL)
Including Richter’s Transformation
5301
BCMA
Multiple myeloma (MM)
Multiple targets

Immunology

Small molecules

Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
3667
TYK2
Systemic lupus erythematosus (SLE)
3667
TYK2
Dermatomyositis (DM)
Multiple targets

Visit our Clinical Trials Portal

Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.

Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.

Our stories

More about our company, science and people

We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos

Partnerships

Work with us!

We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!

Investor Hub

All information for investors…

… centralized in one Investor Hub. Discover how we aim to create value for all our stakeholders.